Heparin-induced thrombocytopenia: a general review
Review published in J Infus Nurs (2007)
Abstract
Unfractionated heparin is widely used for numerous clinical situations. A well-known adverse effect of heparin exposure is thrombocytopenia. Heparin-induced thrombocytopenia is a clinicopathologic syndrome that can be associated with severe complications and significant mortality. The pathophysiology of heparin-induced thrombocytopenia includes an immune-mediated reaction to heparin that activates platelets and results in an acquired hypercoagulability. Diagnosis of heparin-induced thrombocytopenia should incorporate clinical signs and symptoms and laboratory testing for heparin-induced thrombocytopenia antibodies. Therapy should include discontinuation of heparin, initiation of a direct thrombin inhibitor, and eventually therapy with warfarin (only after the platelet count is at least 100 x 10(9)/L).
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
This review describes the immune-mediated pathophysiology of heparin-induced thrombocytopenia, recommends diagnosis via clinical signs and antibody testing, and outlines therapy with heparin discontinuation, a direct thrombin inhibitor, and delayed warfarin until platelet count reaches at least 100 x 10(9)/L.
Why This Matters for Hirudotherapy
This general review covers heparin-induced thrombocytopenia as a clinicopathologic syndrome, describing its immune-mediated pathophysiology, the importance of combining clinical assessment with laboratory antibody testing for diagnosis, and a treatment algorithm of heparin discontinuation, initiation of a direct thrombin inhibitor, and eventual warfarin transition only after platelet recovery to at least 100 × 10⁹/L. The abstract refers generically to direct thrombin inhibitors without naming lepirudin, hirudin, or any specific agent, and does not mention leeches or the leech secretome. Therefore, no specific relevance to hirudotherapy can be established from the abstract text, and the connection is at most indirect. The abstract provides no primary data and no hirudin-specific pharmacology or outcomes.
Citation
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026